June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Leaky Choroidal Nevi: A Clinical, Imaging and Therapeutic Analysis
Author Affiliations & Notes
  • Shahar Frenkel
    Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
  • Gustavo A. Gutiérrez-Vargas
    Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
  • Jacob Pe'er
    Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
  • Footnotes
    Commercial Relationships   Shahar Frenkel, None; Gustavo Gutiérrez-Vargas, None; Jacob Pe'er, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1787. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Shahar Frenkel, Gustavo A. Gutiérrez-Vargas, Jacob Pe'er; Leaky Choroidal Nevi: A Clinical, Imaging and Therapeutic Analysis. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1787.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the clinical and imaging features as well as treatment offered to patients with Leaky Choroidal Nevi and their outcome.

Methods : The charts of patients with a choroidal nevus crossing the temporal arcades inwards and showing leakage on OCT were reviewed. We analyzed the clinical features, findings on ancillary tests (OCT, Color Fundus Picture, Fluorescein Angiography and Eye Ultrasound) and treatment methods used.

Results : Throughout the review of almost 12 years, 17 patients with the above diagnosis presented loss of at least one logMAR line in 57.14% of the cases; improvement in 28.57%, and stability in 14.29%. By Posterior Segment US, an increase of both mean tumor thickness and largest base was of 0.8mm. SRF was the most common finding on OCT. All lesions that required treatment received intravitreal Bevacizumab, with a mean number of injections of 5.41. 25% of these patients presented VA improvement. Although PDT was reserved as a 2-4 line of treatment, 3 out of 4 patients treated with this modality had an anatomical improvement and 1 out of 4 with a functional improvement. Intravitreal Ranibizumab, Focal LASER and TTT were also used.

Conclusions : Leaky Choroidal Nevi is a term proposed for borderline, suspicious lesions with deleterious effects on visual acuity. A short trial of Bevacizumab can be warranted initially and consolidated by PDT if needed. Close follow-up is suggested due to its morbidity and the risk of conversion to Choroidal Melanoma.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×